No Data
No Data
Investor Optimism Abounds Tuoxin Pharmaceutical Group Co.,Ltd. (SZSE:301089) But Growth Is Lacking
Tuoxin Pharmaceutical (301089.SZ) plans to distribute 2.5 yuan for 10 shares to be deducted from interest on May 23
Tuoxin Pharmaceutical (301089.SZ) announced that the company's 2023 equity distribution plan: 2.5 for every 10 shares...
Tuoxin Pharmaceutical (301089.SZ): Actively carry out research on the application of synthetic biology-related technologies in the field of nucleosides and nucleotide products
On May 8, Gelonghui | Tuoxin Pharmaceutical (301089.SZ) announced abnormal stock trading fluctuations. Recently, the company noticed that the Internet and some media published reports on “synthetic biology.” Guided by the principles of systems biology and engineering, synthetic biology takes genomic and biochemical molecular synthesis as the core technology. Through biochemistry, biophysics, and bioinformatics, it continuously designs, transforms, and reshapes biomolecules, biological components, and biological differentiation processes, laying a solid foundation for constructing bioactive biological elements, systems, and artificial cells or organisms. In the field of healthcare, synthesis
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
A-share afternoon review: The Shanghai index closed down 0.13%, and synthetic biology and low-altitude economic concepts had the highest gains
The main A-share index fell slightly. As of the midday close, the Shanghai Index fell 0.13% to 3136.62 points, the Shenzhen Stock Exchange Index fell 0.31%, and the GEM index fell 0.31%.
Tuoxin Pharmaceutical (301089.SZ) announced its 2023 annual results, with net profit of 243 million yuan, a decrease of 15.17%
According to the Zhitong Finance App, Tuoxin Pharmaceutical (301089.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 836 million yuan, an increase of 6.47% over the previous year. Net profit attributable to shareholders of listed companies was 243 million yuan, a year-on-year decrease of 15.17%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 232 million yuan, a year-on-year decrease of 16.07%. Basic earnings per share were $1.93. It is proposed to distribute a cash dividend of 2.5 yuan (tax included) for every 10 shares to all shareholders.
No Data